Airway and systemic inflammation and decline in lung function in patients with COPD

Chest

Volumn 128, Issue 4, 2005, Pages 1995-2004

  Donaldson, Gavin C ^a   Seemungal, Terence A R ^a   Patel, Irem S ^a   Bhowmik, Angshu ^a   Wilkinon, Tom M A ^a   Hurst, John R ^a   MacCallum, Peter K ^a   Wedzicha, Jadwiga A ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Airway; COPD; Inflammatory markers; Systemic

Indexed keywords

BIOCHEMICAL MARKER; FIBRINOGEN; INTERLEUKIN 6;

ADULT; AGE DISTRIBUTION; AGED; AIRWAY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE MARKER; FEMALE; FIBRINOGEN BLOOD LEVEL; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; INFLAMMATION; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL; SPUTUM ANALYSIS;

EID: 27144526596     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.4.1995     Document Type: Article

References (40)

1. Murrey CJL, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Health Study. Science 1990; 274:740-743
2. Thomason M, Strachan DF. Which spirometric indices best predict subsequent death from chronic obstructive pulmonary disease? Thorax 2000; 5:785-788
3. 1: the Lung Health Study. JAMA 1994; 16:1539-1541
4. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57:847-852
5. Kanner RE, Anthontsen NR, Connett JE. Lower respiratory illnesses promote FEV, decline in current smokers but not ex-smokers with mild chmnic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:358-364
6. Di Stefano A, Capelli A, Lusuardi M, et al. Seventy of airflow limitation is associated with seventy of airway inflammation in smokers. Am J Respir Crit Care Med 1998; 158:1277-1285
7. Stãnescu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV, in smokers are associated with increased levels of sputum neutrophils. Thorax 1996; 51:267-271
8. Bhowmik A, Seemungal TAR, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COFD exacerbations. Thorax 2000; 55:114-120
9. Wedzicha JA, Seemungal TAR, MacCallum FK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum 1L-6 levels. Thromb Haemost 2000; 84:210-215
10. Dahl M, Tybjaerg-Hansen A, Vestbo J, et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1008-1011
11. Jones PW, Bosh TK. Quality of life changes in COFD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155:1283-1289
12. Hill AT, Camphell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109:288-295
13. Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonization and the frequency, character, and seventy of COFD exacerbations. Thorax 2002; 57:759-764
14. Wilkinson TMA, Fatel IS, Wilks M, et al. Airway bacterial load and FEV, decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1090-1095
15. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1618-1623
16. Bhowmik A, Seemungal TA, Sapsford RJ, et al Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. Thorax 1998; 53:953-956
17. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957; 17:237-246
18. Zalacain R, Sobradillo V, Amilibia J, et al. Predisposing factors for bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999; 13:343-348
19. Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1608-1613
20. Tyrrell DA, Cohen S, Schlarb JE. Signs and symptoms in common colds. Epidemiol Infect 1993; 111:143-156
21. Isaacs D. Respiratory tract viruses. In: Weatherall DJ, Ledingham JGG, Warrell DA, eds. Oxford textbook of medicine. Oxford, UK: Oxford University Press, 1996; 338
22. Edward LJ. Modern statistical techniques for the analysis of longitudinal data in biomedical research. Pediatr Pulmonol 2000; 30:330-334
23. Alessandri C, Basili S, Violi F, et al. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Thromb Haemost 1994; 72:343-346
24. Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors and long term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 324:1076-1079
25. Short K, Nair R. The effect of age on protein metabolism. Curr Opin Clin Nutr Metab Care 2000; 3:39-44
26. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease. JAMA 1998; 279:1477-1482
27. Lange P, Nyboe J, Appleyard M, et al. Spirometric findings and mortality in never smokers. J Clin Epidemiol 1990; 43:867-873
28. Hole DJ, Watt GCM, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfew and Paisley prospective population study. BMJ 1996; 313:711-715
29. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107:1514-1519
30. Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1414-1418
31. De Godoy I, Donalioe M, Calhoun WJ, et al. Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1994; 150:1453-1455
32. Wouters EF. Chronic obstructive pulmonary disease: 5. Systemic effects of COPD. Thorax 2002; 57:1067-1070
33. Dentener MA, Creutzberg EC, Schols AM, et al. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax 2001; 56:721-726
34. Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003; 58:752-756
35. Vernooy JH, Kucukaycan M, Jacos JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1218-1224
36. Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002; 166:105-110
37. Jones PW, Willits LR, Burge PS, et al. Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003; 21:68-73
38. Sutherland ER, Allmers H, Ayas NT, et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003; 58:937-941
39. Fletcher CM, Peto R, Tinker CM, et al. The natural history of chronic bronchitis and emphysema. Oxford, UK: Oxford University Press, 1976
40. Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14:1015-1022